Novonesis A/S Signals Confident Outlook After Strong Year

Novonesis A/S – Adr ((NVZMY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Novonesis A/S used its latest earnings call to underline a broadly upbeat story of profitable growth and disciplined execution. Management highlighted 7% organic sales expansion for the year, wider margins, strong cash generation and fast payback from recent M&A, while acknowledging currency, country exits and temporary CapEx as manageable headwinds already baked into its 2026 outlook.

Solid Organic Sales Growth Despite Portfolio Pruning

Novonesis delivered 7% organic sales growth for FY2025, with Q4 at 4%, even after exiting certain countries that shaved roughly 1 percentage point off the full year. Reported sales in euro rose 5%, as negative FX masked part of the underlying demand momentum across its biosolutions portfolio.

Strong Profitability and Margin Expansion

Profitability continued to strengthen, with an adjusted EBITDA margin of 37.1% for FY2025, up 100 basis points and in line with guidance of 37%–38%. Adjusted gross margin climbed 240 basis points to 59.1%, and Q4 adjusted EBITDA margin improved to 36.6%, confirming that cost discipline and mix are offsetting macro pressures.

Robust Cash Generation and EPS Upside

Operating cash flow increased by EUR 189 million to EUR 1.22 billion, underscoring the cash generative nature of the business. Free cash flow before acquisitions grew 15% to EUR 770 million, equal to 19% of sales, supporting a 16% rise in diluted adjusted EPS to EUR 1.49 and 15% EPS growth ex-PPA to EUR 1.99.

Successful M&A Integration and Synergy Delivery

The Feed Enzyme Alliance acquisition, closed in June 2025, contributed about 1% to sales and roughly 0.25–0.5 percentage points to margin, in line with expectations. Integration is ahead of plan, with management already achieving the full run rate of cost synergies one year earlier than initially guided, reinforcing confidence in its bolt-on M&A strategy.

Innovation Engine and R&D Firepower

Novonesis underscored its innovation credentials, launching 33 new biosolutions in 2025, including 14 in Q4, with about a quarter of sales coming from products less than five years old. R&D spending exceeded EUR 400 million and is backed by around 10,000 patents, while AI tools have cut lead discovery timelines from years to months, and 85% of 2025 launches are IP-protected.

Sustainability and ESG as Commercial Drivers

Sustainability remains integral to the business model, with 80% of sales aligned to at least one Sustainable Development Goal. The company reported it met all six of its 2025 sustainability targets, including sourcing 100% of its electricity from renewable sources, positioning ESG progress as both a risk mitigant and a commercial advantage.

Divisional Outperformance in Human Health and F&B

Human Health posted 10% organic growth for the year and in Q4, propelled by Dietary Supplements and Advanced Health & Nutrition solutions. Food & Beverages grew 8% organically for the year and 7% in Q4, driven by dairy, baking, meat and plant-based innovations, with products such as Galaya Smooth and Javora Enhance supporting mix and pricing.

Improved Returns and Shareholder-Friendly Capital Allocation

Return metrics improved, with adjusted return on invested capital excluding goodwill reaching 10.1%, more than 20% above the prior pro forma level. The board proposed a total dividend payout of DKK 6.5 per share, equivalent to EUR 0.87 and a 58.4% payout ratio, comfortably within the stated 40%–60% policy range.

Currency Headwinds Weighing on Reported Numbers

Foreign exchange remained a notable drag, reducing FY sales by around 3% and Q4 sales by about 4% versus underlying trends. Management said currency effects compressed the adjusted EBITDA margin by roughly 0.5–1.0 percentage points and, at current spot rates, could trim 2026 euro sales growth by around 2 percentage points.

Country Exits Temporarily Dampening Growth

Strategic exits from certain geographies reduced organic sales growth by about 1 percentage point in 2025, with sharper effects in specific divisions. Food & Health and Food & Beverages each saw roughly 3 percentage points of full-year drag and Food & Beverages faced about a 6 percentage point hit in Q4, with a similar close to 1 percentage point headwind expected in 2026, mainly in the first half.

One-Off Charges and Special Items

Reported results were also affected by EUR 66 million of special items in 2025, tied mainly to transaction, integration and ERP-related expenses. Management guided for around EUR 40 million of special items in 2026 as integration and ERP implementation continue, but stressed that these are non-recurring and do not change the underlying margin trajectory.

Restructuring Costs and Site Closure Effects

Q4 margins reflected one-off expenses linked to operational restructuring, including plant realignment, asset write-downs and closure of a smaller site. These actions weighed on Q4 EBITDA by about 0.5 percentage points but are aimed at sharpening portfolio focus and are expected to support profitability over time.

Mixed Q4 in Planetary Health and Ag/Tech Timing

The Planetary Health division saw organic growth slow to 2% in Q4, with its EBITDA margin down 90 basis points, hit by realignment charges and currencies. Agricultural, Energy & Tech was flat in Q4, as demand in Tech and Agricultural remained lumpy and timing-sensitive against tough comparables, highlighting some quarter-to-quarter volatility.

Q4 Growth Trails Full-Year Momentum

Overall, Q4 organic sales growth of 4% and 2% reported in euro lagged the stronger 7% organic expansion seen for the full year. Management attributed the softer quarter to the combined impact of country exits, currency translation and timing issues, rather than a deterioration in underlying demand.

Elevated CapEx and Temporary Margin Pressure

Capital expenditure rose to EUR 471 million, or 11.3% of sales, about 2 percentage points higher year on year as Novonesis invested to expand production. Guidance calls for CapEx of 12%–14% of sales in 2026 for projects such as U.S. dairy culture capacity and enzyme plants in emerging markets, which may temporarily pressure free cash flow timing despite robust cash generation.

End-Market Uncertainty and Consumer Sentiment Risk

Management flagged softer consumer sentiment, particularly in the U.S., as a key downside risk for 2026, even though the year has started well. They emphasized that the outlook already embeds this uncertainty, implying that any improvement in macro trends could offer upside to current expectations.

Guidance Points to Continued Volume-Led Growth

For 2026, Novonesis guided to 5%–7% organic sales growth, primarily volume-driven and including close to a 1 percentage point drag from country exits. Pricing, sales synergies, the Feed Enzyme Alliance and deferred revenue in Human Health should each add about 1 percentage point, while FX may subtract around 2 points, with an adjusted EBITDA margin targeted at 37%–38%, CapEx at 12%–14% of sales and year-end net debt/EBITDA near 1.7.

Management’s tone throughout the call suggested a business in control of its levers, balancing investment and shareholder returns while navigating currency and macro headwinds. For investors, the key takeaways are resilient organic growth, improving profitability and a confident, though measured, outlook for 2026 that builds on a strong foundation in innovation and sustainability.